Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachna Bhandari

Dermatology San Antonio, TX Medical Doctor

NPI 1316235328 CMS profile 2780970

18707 Hardy Oak Blvd Ste 101, San Antonio, TX 78258

Open in the dashboard

General payments

$52,951

869 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachna Bhandari of San Antonio, TX is reported in the CMS Open Payments database as having received $52,951 across 869 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,835 185
2024 General $10,448 154
2023 General $5,402 121
2022 General $2,692 146
2021 General $5,546 76
2020 General $1,688 72
2019 General $2,341 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachna Bhandari
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Rachna Bhandari were reported at $24,835. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Rachna Bhandari Dermatology median Middle half National median
2019 $2,341 $454 $129–$1,240 $163
2020 $1,688 $235 $81–$756 $114
2021 $5,546 $377 $108–$1,108 $132
2022 $2,692 $514 $143–$1,391 $149
2023 $5,402 $607 $159–$1,674 $160
2024 $10,448 $751 $204–$1,903 $164
2025 $24,835 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $29,146 165 payments
  2. Journey Medical Corporation $4,759 23 payments
  3. AbbVie, Inc. $3,452 134 payments
  4. Dermavant Sciences, Inc. $2,860 27 payments
  5. Genzyme Corporation $1,416 51 payments
  6. UCB, Inc. $1,265 42 payments
  7. Regeneron Healthcare Solutions, Inc. $1,160 55 payments
  8. Sun Pharmaceutical Industries Inc. $900 54 payments
  9. Incyte Corporation $583 50 payments
  10. Lilly USA, LLC $578 22 payments
  11. Other $6,832 246 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,368 12 payments
  2. Food and Beverage $20,046 840 payments
  3. Consulting Fee $3,000 2 payments
  4. Travel and Lodging $765 4 payments
  5. Education $468 9 payments
  6. Honoraria $305 2 payments
Products named General payments · program years 2019–2025
  1. NEMLUVIO $20,610 48 payments
  2. VTAMA $3,049 32 payments
  3. Accutane $2,214 11 payments
  4. SKYRIZI $1,577 45 payments
  5. DUPIXENT Immunology $1,545 49 payments
  6. RINVOQ $1,294 67 payments
  7. TargaDox $1,254 5 payments
  8. TREMFYA $1,019 20 payments
  9. Bimzelx $916 31 payments
  10. DUPIXENT Inflammation And Immunology $865 44 payments
  11. Other $11,650 576 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

204

Median for Dermatology: 534

Drug cost

$94,898

Median for Dermatology: $67,151

Branded share of claims

18.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 19 $91,504
Ketoconazole Generic 29 $791
Clobetasol Propionate Generic 37 $762
Ciclopirox Generic 22 $478
Valacyclovir Valacyclovir Hcl Brand 19 $393
Clotrimazole Generic 33 $305
Spironolactone Generic 14 $304
Triamcinolone Acetonide Generic 16 $218
Mupirocin Generic 15 $144

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$57,097

Medicare's payments for the services billed

Medicare patients

231

Average age 73

Services billed

1,690

148 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 50%
Ischemic heart disease 28%
Diabetes 21%
Chronic kidney disease 18%
Osteoporosis 18%
Depression 16%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$344 — —
DUPIXENT
$336 — —
VTAMA
$320 — —
RINVOQ
$279 — —
Bimzelx
$232 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

869 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record